IL6 and colorectal carcinoma: However, the anti-IL-6 monoclonal antibody Siltuximab did not induce objective clinical responses in patients with advanced and refractory CRC in phase I/II clinical trial [36], suggesting that blockade of a single factor with a dual role in this complex environment is insufficient.